Tumor Biology

, Volume 36, Issue 11, pp 8491–8497 | Cite as

High density of tryptase-positive mast cells in patients with multiple myeloma: correlation with parameters of disease activity

  • Maria Devetzoglou
  • Rodanthi Vyzoukaki
  • Maria Kokonozaki
  • Athina Xekalou
  • Constantina A. Pappa
  • Anastasia Papadopoulou
  • Athanasios Alegakis
  • Nikolaos Androulakis
  • Michael G. Alexandrakis
Research Article
  • 86 Downloads

Abstract

Multiple myeloma (MM) is a plasma cell neoplasm characterized by bone marrow infiltration from malignant plasma cells. Mast cells play an important role in inflammation and angiogenesis in malignant diseases. The aim of the study was to evaluate the mast cell density in bone marrow of untreated MM patients with markers of disease activity such as serum interleukin-6 (IL-6), B2M, and C-reactive protein (CRP), the grade of bone marrow infiltration, and the levels of produced paraprotein. We studied 86 newly diagnosed MM patients (46 males, 40 females, mean age 59 ± 13.7 years). Thirty of them reached plateau phase after chemotherapy and 20 healthy volunteers. According to the criteria of International Staging System (ISS) staging system, 23 patients had stage I, 30 had stage II, and 33 had stage III. The serum concentrations of CRP, B2M, and IL-6, and the mast cell density (MCD) values were significantly higher in MM patients’ group (1.6 ± 1.8, 4.3 ± 2.9, 7.1 ± 5.1, and 9 ± 4.8), in comparison with those found in control group (0.4 ± 0.1, 1.5 ± 0.6, 1.1 ± 0.5, and 1.9 ± 0.7; p < 0.001 in all the cases). Significant differences were found between the grade of infiltration in bone marrow, and the paraprotein values in patients’ serum before and after chemotherapy. Furthermore, there was a significant correlation between the MCD values and the prognostic markers CRP (r = 0.452, p < 0.0001), IL-6 (r = 0.475, p < 0.0001), bone marrow infiltration (r = 0.333, p < 0.0002), and serum paraprotein levels(r = 0.221, p < 0.04). High MCD values strengthen the hypothesis that mast cells participate in the pathogenesis of disease progression and may be used as an indicator of the disease activity.

Keywords

Mast cells Multiple myeloma Acute phase proteins Angiogenesis Prognosis 

Notes

Conflict of interest

None

References

  1. 1.
    Kyle RA, Child JA, Anderson K, et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749–75.CrossRefGoogle Scholar
  2. 2.
    Sezer O, Jakob C, Euker J, et al. Serum levels of the angiogenic cytokines basic fibroblast grow factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol. 2001;66:83–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Giuliani N, Storti P, Bolzoni M. Angiogenesis and multiple myeloma. Cancer Microenviron. 2011;4:325–37.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Bellamy WT. Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Sesmin Oncol. 2001;28:551–9.CrossRefGoogle Scholar
  5. 5.
    De Souza Jr DA, Toso VD, Campos MR, et al. Expression of mast cell proteases correlates with mast cell maturation and angiogenesis during tumor progression. PLoS One. 2012;7:e40790.CrossRefGoogle Scholar
  6. 6.
    Pappa CA, Tsirakis G, Devetzoglou M, et al. Bone marrow mast cell dencity correlates with serum levels of VEGF and CXC chemokines ENA-78 and GRO-α in multiple myeloma. Tumor Biol. 2014;35(6):5647–51.CrossRefGoogle Scholar
  7. 7.
    Nico B, Magnieri D, Crivellato E, et al. Mast cells contribute to vasculogenic mimicry in multiple myeloma. Stem Cells Dev. 2008;17:19–22.CrossRefPubMedGoogle Scholar
  8. 8.
    Pappa CA, Tsirakis G, Kanellou P, et al. Monitoring serum levels ELR+CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma. Cytokine. 2011;56:616–20.CrossRefPubMedGoogle Scholar
  9. 9.
    Pappa CA, Tsirakis G, Roussou P, et al. Positive correlation between bone marrow mast cell density and ISS prognostic index in patients with multiple myeloma. Leuk Res. 2013;37(12):1628–31.CrossRefPubMedGoogle Scholar
  10. 10.
    Tsirakis G, Pappa CA, Kaparou M, et al. The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma. Tumor Biol. 2013;34:859–64.CrossRefGoogle Scholar
  11. 11.
    Alexandrakis MG, Passam FH, Ganotakis ES, et al. The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma. Clin Lab Haematol. 2003;25:41–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Kyriakou D, Papadaki H, Eliopoulos AG, et al. Serum soluble IL-6 receptor concentrations correlate with stages of multiple myeloma defined by serum β2-microglobulin and C-reactive protein. Int J Hematol. 1997;66:367–71.CrossRefPubMedGoogle Scholar
  13. 13.
    Durie BG, Stock-Novak D, Salmon SE. et al.Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood. 1990;75:823–30.PubMedGoogle Scholar
  14. 14.
    Alexandrakis MG, Passam FH, Boula A, et al. Relashioship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Ann Hematol. 2003;82:19–23.PubMedGoogle Scholar
  15. 15.
    Rossi D, Fangazio M, De Paoli L, et al. Beta -2-Microglobulin Is an Indipendent Predictor of Progression in Asymptomatic Multiple Myeloma. Cancer. 2010;116:2188–200.PubMedGoogle Scholar
  16. 16.
    Ribatti D, Crivellato E, Molica S. Mast cells and angiogenesis in haematological malignancies. Leuk Res. 2009;33:876–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Benitez-Bibiesca L, Wong A, Utrera D, et al. The role of mast cell tryptase in neoangiogenesis of premalignant and malignant lesions of the uterine cervix. J Histochem Cytochem. 2001;49:1061–2.CrossRefGoogle Scholar
  18. 18.
    Tomita M, Matsuzaki Y, Onitsuka T. Effect of mast cells on tumor angiogenesis in lung cancer. Ann Thorac Surg. 2000;69:1686–90.CrossRefPubMedGoogle Scholar
  19. 19.
    Fajardo I, Peiler G. Human mast cell beta-tryptase is a gelatinase. J Immunol. 2003;171:1493–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Varkonyi J, Bjzik E, Fazakas A, et al. Short or long survival in multiple myeloma.A simple method for determining the prognosis. Pathol Oncol Res. 2009;15:383–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Lauta VM. A review of the Cytokine Network in Multiple Myeloma. Cancer. 2003;97:2440–52.CrossRefPubMedGoogle Scholar
  22. 22.
    Blade J, Cibeira MT, Fernandez de Larrea C, et al. Multiple myeloma. Ann Oncol. 2010;21(7):vii313–9.Google Scholar
  23. 23.
    Shah J, Bladé J, Sonneveld P, Harousseau JL, Lantz K, Londhe A, et al. Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression. Cancer. 2011;117:3758–62.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Anderson KC. Multiple myeloma, a clinical overview. Oncology. 2011;25(suppl):3–9.PubMedGoogle Scholar
  25. 25.
    Dundar E, Oner U, Peker BC, Metintas M, Isiksoy S, Ak G. The significance and relationship between mast cells and tumour angiogenesis in non-small cell lung carcinoma. J Int Med Res. 2008;36(1):88–95.CrossRefPubMedGoogle Scholar
  26. 26.
    Tomita M, Matsuzaki Y, Onitsuka T. Effect of mast cells on tumor angiogenesis in lung cancer. Ann Thorac Surg. 2000;69(6):1686–90.CrossRefPubMedGoogle Scholar
  27. 27.
    Ribatti D, Ennas MG, Vacca A, Ferreli F, Nico B, Orru S, et al. Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Investig. 2003;33(5):420–5.CrossRefGoogle Scholar
  28. 28.
    Ribatti D, Crivellato E. Mast cells, angiogenesis and cancer. Adv Exp Med Biol. 2011;716:270–88.CrossRefPubMedGoogle Scholar
  29. 29.
    Dunphy CH. Evaluation of mast cells in myeloproliferative disorders and myelodysplastic syndromes. Arch Pathol Lab Med. 2005;129(2):219–22.PubMedGoogle Scholar
  30. 30.
    Wilkins BS, Buchan SL, Webster J, Jones DB. Tryptase-positive mast cells accompany lymphocytic as well as lymphoplasmacytic lymphoma infiltrates in bone marrow trephine biopsies. Histopathology. 2001;39(2):150–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Nakayama T, Yao L, Tosato G. Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. J Clin Invest. 2004;114(9):1317–25.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Maria Devetzoglou
    • 1
  • Rodanthi Vyzoukaki
    • 2
  • Maria Kokonozaki
    • 2
  • Athina Xekalou
    • 4
  • Constantina A. Pappa
    • 3
  • Anastasia Papadopoulou
    • 2
  • Athanasios Alegakis
    • 5
  • Nikolaos Androulakis
    • 2
  • Michael G. Alexandrakis
    • 1
    • 2
  1. 1.Department of HeamatologyUniversity Hospital of HeraklionHeraklionGreece
  2. 2.Laboratory of HeamatologyUniversity Hospital of HeraklionHeraklionGreece
  3. 3.Department of Internal MedicineVenizeleion General Hospital of HeraklionHeraklionGreece
  4. 4.Department of PathologyVenizeleion General Hospital of HeraklionHeraklionGreece
  5. 5.School of MedicineUniversity of CreteHeraklionGreece

Personalised recommendations